ARGX vs GILD vs INSM Stock Comparison

Argenx Se, Gilead Sciences and Insmed Prices as of Nov 13, 2026 Peers: Industry group
ARGX Argenx Se
$960.04 +17.3% 1M +7.7% 1Y
Market cap
$58.99B
P/E
31.4x
Revenue (TTM)
$5.82B
Div. yield
–
Biotechnology Healthcare
2 wins
GILD Gilead Sciences, Inc.
$168.08 +9.5% 1M +34.2% 1Y
Market cap
$210.36B
P/E
–
Revenue (TTM)
$30.99B
Div. yield
–
Biotechnology Healthcare
4 wins
INSM INSMED Inc
$121.16 +23.9% 1M -36.6% 1Y
Market cap
$27.21B
P/E
–
Revenue (TTM)
$1.52B
Div. yield
–
Biotechnology Healthcare
3 wins

Head to Head

9 decided of 12

Gilead Sciences leads on 4 of the 12 questions below (Gilead Sciences 4, Insmed 3, Argenx Se 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionARGXGILDINSMLeader
Larger companyMarket capitalisation $58.99B $210.36B $27.21B GILD
Cheaper on earningsLower P/E, profitable companies only 31.4x -54.5x -44.9x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 32.8x — — –
Faster revenue growthRevenue growth, trailing twelve months +61.5% +6.5% +240.0% INSM
More profitableNet margin, trailing twelve months 32.3% -12.5% -39.9% ARGX
Better return on capitalReturn on invested capital — -6.1% -41.1% GILD
Less leveragedLower net debt / EBITDA — 43.8x 1.1x INSM
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +7.7% +34.2% -36.6% GILD
Better 5-year returnAnnualised price return, 5 years +25.4%/yr +20.0%/yr +30.6%/yr INSM
Less volatileAnnualised volatility, 1 year 37.7% 27.5% 62.2% GILD
Higher overall scoreMean of the five percentile scores vs peers 92/100 61/100 66/100 ARGX

Percentile Scorecard

ARGXGILDINSM

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisARGXGILDINSM
Valuation 82 #122 of 660 89 #71 of 660 70 #201 of 660
Growth 96 #27 of 619 34 #408 of 619 85 #91 of 619
Profitability 99 #9 of 595 85 #91 of 595 69 #186 of 595
Financial Health – 22 #530 of 683 37 #428 of 683
Shareholder Returns – 75 #116 of 459 67 #153 of 459
Overall 92 61 66
  • ARGX ranked among 695 companies in Pharmaceuticals and Biotechnology
  • GILD ranked among 695 companies in Pharmaceuticals and Biotechnology
  • INSM ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodARGXGILDINSMSPY
1 month +17.3%+9.5%+23.9% -2.0%
3 months +12.8%+21.5%-2.1% -2.8%
6 months +20.1%+29.7%+11.0% +2.0%
Year to date +14.2%+36.9%-30.4% +10.6%
1 year +7.7%+34.2%-36.6% +12.2%
3 years +96.0%+124.9%+393.7% +68.1%
3 years, per year +25.2%+31.1%+70.3% +18.9%
5 years +210.1%+149.1%+280.3% +61.4%
5 years, per year +25.4%+20.0%+30.6% +10.1%
10 years —+119.9%+738.5% +248.5%
10 years, per year —+8.2%+23.7% +13.3%

Risk

MeasureARGXGILDINSMSPY
Volatility, 1Y 37.7%27.5%62.2% 13.6%
Downside volatility, 1Y 35.2%24.0%61.0% 13.9%
Beta vs S&P 500, 1Y 0.540.390.55 1.00
Return / volatility, 1Y 0.201.25-0.59 0.90
Max drawdown, 5Y -38.2%-29.4%-56.5% -25.4%
From 52-week high -9.3%-3.7%-42.7% -3.2%
52-week high $1,058.90$174.48$211.41 $779.14
52-week low $663.93$118.30$91.88 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleARGXGILDINSM
P/E now vs peer median 31.4xmedian 17.0x -54.0xmedian 17.0x -43.8xmedian 17.0x
P/S now vs peer median 10.2xmedian 8.4x 6.7xmedian 8.4x 17.5xmedian 8.4x
EV/EBITDA now vs peer median —median 14.6x 505.3xmedian 14.6x -48.6xmedian 14.6x
P/FCF now vs peer median —median 19.0x 15.1xmedian 19.0x -42.3xmedian 19.0x
P/B now vs peer median —median 2.0x 16.0xmedian 2.0x 36.6xmedian 2.0x
PEG now vs peer median 0.30median 0.43 1.40median 0.43 -2.40median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsARGXGILDINSM
Revenue $5.82B $30.99B $1.52B
Gross profit $5.24B $24.77B $1.28B
Operating income $1.74B -$2.36B -$563.99M
Net income $1.88B -$3.86B -$605.67M
Free cash flow – $13.78B -$627.58M
R&D $1.80B $6.33B $944.39M
EPS (diluted) $28.43 $-3.09 $-2.77
Cash & equivalents – $6.44B $396.60M
Total debt – $26.23B $555.09M
Shares (diluted) 66.03M 1.25B 218.79M
Enterprise value $58.99B $185.47B $22.25B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricARGXGILDINSM
P/E 31.4x -54.0x -43.8x
P/FCF – 15.1x -42.3x
P/Operating cash flow – 14.4x -44.6x
P/S 10.2x 6.7x 17.5x
P/B – 16.0x 36.6x
P/Tangible book – -543.2x 45.2x
EV/EBITDA – 505.3x -48.6x
EV/EBIT 34.1x -96.7x -46.1x
EV/Revenue 10.2x 7.4x 17.1x
EV/FCF – 16.6x -41.4x
EV/Operating cash flow – 15.8x -43.6x
PEG (3Y EPS CAGR) 0.30 1.40 -2.40

Growth

14 metrics
MetricARGXGILDINSM
Revenue growth (1Y) 61.5% 6.5% 240.0%
Revenue CAGR (3Y) 80.5% 4.2% 75.6%
Gross profit growth (1Y) 62.2% 8.2% 274.9%
Gross profit CAGR (3Y) 80.0% 4.7% 79.8%
Operating income growth (1Y) 120.6% -122.5% 51.3%
Operating income CAGR (3Y) 85.1% -31.7% 6.2%
Net income growth (1Y) 22.5% -147.6% 48.8%
Net income CAGR (3Y) 115.5% -38.5% 5.8%
EPS growth (1Y) 20.9% -147.7% 50.5%
EPS CAGR (3Y) 104.8% -38.6% 18.2%
Operating cash flow growth (1Y) – 49.8% 32.6%
Operating cash flow CAGR (3Y) – 19.9% -5.4%
Free cash flow growth (1Y) – 50.4% 30.7%
Free cash flow CAGR (3Y) – 20.6% -6.2%

Profitability

14 metrics
MetricARGXGILDINSM
Gross margin 90.0% 79.9% 84.4%
EBITDA margin – 1.5% -35.1%
Operating margin 29.9% -7.6% -37.1%
Pretax margin 32.6% -8.2% -39.4%
Net margin 32.3% -12.5% -39.9%
FCF margin – 44.5% -41.3%
Operating cash flow margin – 46.7% -39.2%
Return on equity – -31.2% -81.9%
Return on assets – -7.7% -28.1%
Return on invested capital – -6.1% -41.1%
Return on capital employed – -6.2% -36.0%
Asset turnover – 0.6x 0.7x
Cash conversion (OCF / net income) – -3.7x 1.0x
Stock comp / revenue – 2.9% 11.0%

Financial Health

11 metrics
MetricARGXGILDINSM
Debt / assets – 51.0% 24.9%
Debt / equity – 2.0x 0.8x
Net debt / EBITDA – 43.8x 1.1x
Debt / FCF – 1.9x -0.9x
Liabilities / assets – 74.6% 67.4%
Equity / assets – 25.4% 32.6%
Interest coverage 10,120x -2.3x -5.5x
Current ratio – 1.4x 2.9x
Quick ratio – 1.0x 2.4x
Cash ratio – 0.5x 1.9x
Altman Z-score – 3.90 7.36

Shareholder Returns

7 metrics
MetricARGXGILDINSM
Dividend yield – 1.9% –
Net buyback yield – 0.5% -0.4%
Shareholder yield – 2.5% -0.4%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusARGXGILDINSM
Forward P/E 32.8xFY2026 – –
EPS, next fiscal year $29.27FY2026 $-0.84FY2026 $-1.68FY2026
EPS growth, next FY +49.6%FY2026 -110.3%FY2026 –
EPS growth, the year after +32.0% – –
Revenue, next fiscal year $6.16BFY2026 $29.15BFY2026 $1.99BFY2026
Revenue growth, next FY +44.9%FY2026 -1.0%FY2026 +227.7%FY2026
Revenue growth, the year after +24.0% +18.3% +59.5%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersARGXGILDINSM
Held by institutions 46.1% 89.6% 100.0%
Institutions holding 506 2,293 671
Change in shares held, QoQ -2.0% +5.1% +3.4%
Institutions buying 263 1,113 369
Institutions selling 162 853 230
Buyers to sellers 1.62 1.30 1.60

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ARGXGILDINSM
ARGX 1.00 0.26 0.27
GILD 0.26 1.00 0.19
INSM 0.27 0.19 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ARGX, GILD and INSM?

Gilead Sciences (GILD) is the largest by market capitalisation: Argenx Se (ARGX) $58.99B, Gilead Sciences (GILD) $210.36B, Insmed (INSM) $27.21B.

Which company is growing faster?

Insmed (INSM) grew revenue fastest over the trailing twelve months: Argenx Se (ARGX) +61.5%, Gilead Sciences (GILD) +6.5%, Insmed (INSM) +240.0%.

Which company is more profitable?

Argenx Se (ARGX) has the highest net margin (Argenx Se (ARGX) 32.3%, Gilead Sciences (GILD) -12.5%, Insmed (INSM) -39.9%). On return on invested capital, Gilead Sciences (GILD) leads (Gilead Sciences (GILD) -6.1%, Insmed (INSM) -41.1%).

Which stock has performed better?

Over the past year Gilead Sciences (GILD) returned the most: Argenx Se (ARGX) +7.7%, Gilead Sciences (GILD) +34.2%, Insmed (INSM) -36.6%. Over five years, Insmed (INSM) compounded fastest (Argenx Se (ARGX) +25.4%/yr, Gilead Sciences (GILD) +20.0%/yr, Insmed (INSM) +30.6%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Gilead Sciences (GILD) has been the steadiest (Argenx Se (ARGX) 37.7%, Gilead Sciences (GILD) 27.5%, Insmed (INSM) 62.2%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ARGX, GILD and INSM?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Gilead Sciences (GILD) leads on 4. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.